FDA Explains Effects Of CBD And Marijuana Compounds Based On Sex And Gender Differences
FDA has been especially active in the cannabis space since the 2018 Farm Bill
The Food and Drug Administration (FDA) announced on Tuesday that it will be hosting a public meeting in November to discuss gender and sex differences in the effects of CBD and other cannabinoids.
In a notice set to be published in the Federal Register on Wednesday, FDA’s Office of Women’s Health announced the event, emphasizing that as interest in CBD and other derivatives of marijuana and hemp continues to grow, there’s a need to explore the science of these cannabinoids in the context of gender and sex. That’s particularly true when it comes to cannabis use among pregnant women, the agency said.
“Researchers, educators, clinicians, and patients may benefit from attending this multidisciplinary scientific conference on CBD and other cannabinoids,” FDA said. “Presentations will address patient and healthcare provider perspectives on CBD and other cannabinoid use, sex differences in the effects of CBD and other cannabinoids, use of CBD and other cannabinoids in pregnancy, and government agency perspectives on CBD research and evaluation.”
“FDA recognizes the significant public interest in cannabis and cannabis-derived compounds, particularly CBD. However, there are many unanswered questions about the science, safety, and quality of products containing CBD. The Agency is working on answering these questions through ongoing efforts including feedback from a FDA hearing and information and data gathering through a public docket.”
To Read The Rest Of This Article On Marijuana Moment, Click Here
